<DOC>
	<DOCNO>NCT01146782</DOCNO>
	<brief_summary>This prospective study Attune Sleep Apnea System treatment obstructive sleep apnea . The objective study demonstrate safety effectiveness Attune Sleep Apnea System support FDA marketing clearance device .</brief_summary>
	<brief_title>Study Sleep Apnea System Treatment Obstructive Sleep Apnea</brief_title>
	<detailed_description />
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<criteria>1 . Subject age 18 80 . 2 . Diagnosis OSA , base ODI 1060 ( assess per home screening night ) . 3 . Subject fluent English understands Study protocol willing able comply Study requirement sign inform consent form . 4 . BMI &lt; 40 . 5 . Subject least one molar four quadrant mouth ( right upper , right low , leave upper , leave low ) . 6 . Subject proper mouthpiece fit , assess home screening night ( See section 8.3 ) . 1 . OSA treatment within two week prior Medical/Dental screen visit . 2 . Poor nasal patency evidence Peak Nasal Inspiratory Flow ( PNIF ) less 75 l/min ( assessed baseline medical visit ) . In addition , ongoing process condition limit nasal breathe indication thereof , include : obligate mouthbreathing , persistent blockage one nostrils result inability sleep mouth close , chronic nasal congestion , chronic allergic rhinitis , intermittent allergic rhinitis respond nonsedating/nonstimulating medical therapy . 3 . Oral cavity infection oral dental condition problem would limit subject use Attune Sleep Apnea System ( e.g . denture , loose tooth/teeth , temporomandibular joint ( TMJ ) condition , oral dental condition Investigator believe could exacerbate Attune Sleep Apnea System . 4 . Prior use Attune Sleep Apnea System . 5 . History OSA surgical treatment include uvulopalatopharyngoplasty surgery ( UPPP ) , maxillomandibular advancement surgery ( MMA ) , radio frequency ( RF ) ablation treatment , palatal stent device , etc . 6 . Current use use within previous 2 week medication agent may affect sleep PSG , include : 1 . Hypnotics , anxiolytic , anticonvulsant , sedate antihistamine , stimulant , sedate antidepressant medication likely affect neurocognitive function and/or alertness . Patients stable selective serotonin reuptake inhibitor ( SSRI ) therapy &gt; 3 month expect remain therapy Study duration , may continue SSRI treatment . 2 . Consumption &gt; 500mg caffeine per day ( e.g . &gt; 8 colatype beverage , &gt; 5 cup coffee ) . 3 . Any known illicit drug use abuse within past year , failure pas drug urine screen test , alcohol breathalyzer test result 0.05 % BAL . 4 . Smokers smoke night ( interference PSG ) . 7 . Any concomitant diagnose suspected sleep chronic neurological disorder , OSA , include insomnia , central sleep apnea . 8 . Currently work night , rotate night shift , plan travel across four time zone require Study period , within two week prior Study enrollment , sleep schedule compatible sleep lab practice . 9 . Potential sleep apnea complication , opinion investigator , may affect health safety participant , include : low blood oxygen , recent nearmiss prior automobile accident due sleepiness , report history severe cardiovascular disease ( include NYHA class III IV heart failure , CAD angina MI/stroke past 6 month , uncontrolled hypertension hypotension , cardiac arrhythmia ) , report respiratory disorder , use medication treatment may pose additional risk subject confound result Study . 10 . Female subject pregnant intend become pregnant study period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>